Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc.（JSPR）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · JSPR · 截至 2025年9月30日
股东结构概览
64
机构持有人数
▼ 4 vs Q2
$47.82M
机构持仓总市值
▼ $21.64M vs Q2
16.25M
总流通股
freeFloat 84.78%
20.16M
13F 申报持股数
▲ 7.64M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
JSPR 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
VELAN CAPITAL INVESTMENT MANAGEMENT LP biological products, (no diagnostic substances) | 2.67M | 17.76% | 17.76% | $6.21B | Nov 14, 2025 | ▲ 1.23M |
SOLEUS CAPITAL MANAGEMENT, L.P. biological products, (no diagnostic substances) | 1.49M | 9.95% | 9.95% | $3.56B | Nov 14, 2025 | — held |
ACORN CAPITAL ADVISORS, LLC biological products, (no diagnostic substances) | 1.38M | 9.20% | 9.20% | $3.29B | Nov 17, 2025 | NEW |
KINGDON CAPITAL MANAGEMENT, L.L.C. biological products, (no diagnostic substances) | 1.32M | 8.82% | 8.82% | $3.15B | Nov 14, 2025 | ▲ 640.1K |
ROCK SPRINGS CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 1.10M | 7.33% | 7.33% | $2.62B | Nov 14, 2025 | ▲ 555.6K |
CARLYLE GROUP INC. biological products, (no diagnostic substances) | 1.07M | 7.10% | 7.10% | $2.53B | Nov 7, 2025 | — held |
WOODLINE PARTNERS LP biological products, (no diagnostic substances) | 1.04M | 6.92% | 6.92% | $2.47B | Nov 14, 2025 | NEW |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 1.03M | 6.88% | 6.88% | $2.46B | Nov 7, 2025 | ▲ 408.2K |
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. biological products, (no diagnostic substances) | 1.03M | 6.85% | 6.85% | $2.45B | Nov 14, 2025 | ▲ 325.2K |
PROPEL BIO MANAGEMENT, LLC biological products, (no diagnostic substances) | 1.03M | 6.85% | 6.85% | $2.45B | Nov 12, 2025 | NEW |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
15
增持
+4.74M 股13
新建仓
首次建仓16
减持
−749.8K 股0
清仓
完全退出净股数变化（前50家）
+3.99M
+4.74M / −749.8K
净新增持仓人
+12
新建 13 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
JSPR 内幕交易记录
数据来源：SEC Form 4
近期内部人员净买入。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
15
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Mahal Jeetinder Singh CEO and President | Feb 6, 2026 | Award | 500,000 | $1.35 | $675.0K | 500.0K | Form 4 ↗ |
MARTELL RON President, CEO and Director | Jan 2, 2026 | Award | 234,000 | $1.84 | $430.6K | 234.0K | Form 4 ↗ |
Mahal Jeetinder Singh Chief Operating Officer | Jan 2, 2026 | Award | 90,000 | $1.84 | $165.6K | 90.0K | Form 4 ↗ |
CROSS HERB Chief Financial Officer | Jan 2, 2026 | Award | 90,000 | $1.84 | $165.6K | 90.0K | Form 4 ↗ |
WIGGANS THOMAS G director | Sep 22, 2025 | Purchase | 41,000 | $2.43 | $99.6K | 41.0K | Form 4 ↗ |
WIGGANS THOMAS G director | Sep 22, 2025 | Purchase | 41,000 | $2.92 | $119.7K | 41.0K | Form 4 ↗ |
Lucas Svetlana director | Sep 22, 2025 | Purchase | 20,000 | $2.43 | $48.6K | 20.0K | Form 4 ↗ |
Lucas Svetlana director | Sep 22, 2025 | Purchase | 20,000 | $2.92 | $58.4K | 20.0K | Form 4 ↗ |
MARTELL RON President and CEO | Sep 22, 2025 | Purchase | 41,000 | $2.43 | $99.6K | 74.1K | Form 4 ↗ |
MARTELL RON President and CEO | Sep 22, 2025 | Purchase | 41,000 | $2.92 | $119.7K | 41.0K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Jasper Therapeutics, Inc.（JSPR）主要由机构投资者持有，机构持股比例约为 100.0%。公司内部人员持股约 15.22%，散户及公众持股约占剩余的 0.00%。
Jasper Therapeutics, Inc. 最大机构股东为 VELAN CAPITAL INVESTMENT MANAGEMENT LP，截至 September 30, 2025 持有约 2.67 million 股，占总流通股的 17.76%。
目前共有 64 家机构持有 JSPR 股票，合计持仓市值约 $47,815,871，数据来源为最新 SEC 13F 申报。
常见问题
JSPR ownershipJasper Therapeutics, Inc.（JSPR）主要由机构投资者持有，机构持股约 100.0%。最大股东为 VELAN CAPITAL INVESTMENT MANAGEMENT LP，持股比例 17.76%。内部人员持股约 15.22%。数据来源 SEC Form 13F，截至 September 30, 2025。